Non-peptide GLP-1 agonist

How GLP-1 receptor agonists work — receptors, gastric emptying, and the satiety pathway.

Definition

A small organic molecule that activates the GLP-1 receptor without being built from a peptide chain. Survives stomach acid and digestive enzymes intact, eliminating the food-restriction requirement that hampers oral peptide drugs like Rybelsus. Foundayo (orforglipron) is the first FDA-approved non-peptide GLP-1 agonist (April 2026), opening a class of oral pills that may replace injections for patients with moderate weight-loss needs.

Foundayo drug overview →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in Mechanism

GLP-1 receptor
GIP receptor
Dual agonist
Gastric emptying
Food noise
Triple agonist
Amylin
GLP-1 tachyphylaxis
A1C (glycated hemoglobin)
MASH / MASLD

Looking for more depth?

Foundayo drug overview
Browse the full GLP-1 glossary (61 terms across 8 categories)
Research articles — primary-source deep dives
Tools and calculators
Compare GLP-1 telehealth providers